Li, Weichao https://orcid.org/0000-0001-6875-7315
Wei, Qijia https://orcid.org/0000-0002-1633-9880
Llanos, Manuel https://orcid.org/0000-0002-9120-4951
Gathmann, Clara https://orcid.org/0009-0002-9426-9774
Governa, Paolo https://orcid.org/0000-0002-5976-780X
Chiu, Tzu-Yuan https://orcid.org/0000-0001-8702-9268
Wozniak, Jacob M. https://orcid.org/0000-0002-2453-0861
Jadhav, Appaso M.
Holcomb, Matthew https://orcid.org/0000-0002-8409-4344
Cravatt, Jacob
Dongre, Ashok
Huang, Mia L. https://orcid.org/0000-0001-9909-9554
Forli, Stefano https://orcid.org/0000-0002-5964-7111
Parker, Christopher G. https://orcid.org/0000-0001-8509-9289
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI182439)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM142462)
Article History
Received: 18 July 2025
Accepted: 30 March 2026
First Online: 5 May 2026
Competing interests
: C.G.P. is a founder of and scientific advisor to Belharra Therapeutics, a biotechnology company interested in using chemical proteomic methods to develop small-molecule therapeutics. A.D. is an employee of Bristol Myers Squibb. All other authors declare no competing interests.